Alexion Recalls Certain Lots of Intravenous Drug Soliris

US drugmaker Alexion Pharmaceuticals said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain.

The company said the recall was related to its earlier manufacturing process, which had prompted a similar recall in November.

Alexion initiated the recall due to the presence of visible particles found in a single lot of Soliris during a test, it said in a statement.

The company said it did not expect the recall to have any financial impact or interrupt supply of the drug.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.